SCHEMBL25925924

SCHEMBL25925924

COc1ccc(O)c(/N=N/c2ccnn2C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.46
NPC1 O15118 7/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
MAPT P10636 4/20 0.46
MAPK1 P28482 3/20 0.46
KMT2A Q03164 7/20 0.42
MEN1 O00255 6/20 0.42
POLB P06746 3/20 0.42
HSP90AA1 P07900 2/20 0.40
KCNH2 Q12809 1/20 0.40
KDM4E B2RXH2 2/20 0.40
OPRK1 P41145 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25925873 0.86 RAB9A (0.36) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL25925862 0.82 MAPT (0.34) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL25925911 0.74 EGFR (0.49) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL18250390 0.72 KMT2A (0.49) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL25925704 0.72 MAPT (0.33) RAB9AL3MBTL1MAPTMAPK1KMT2A
SCHEMBL25925882 0.72 AHR (0.36) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL28532661 0.72 MEN1 (0.57) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL25925941 0.72 KCNH2 (0.34) KCNH2
SCHEMBL25925933 0.72 PTGS1 (0.41) RAB9ANPC1L3MBTL1MAPTMAPK1
SCHEMBL25926077 0.71 TSHR (0.36) RAB9ANPC1L3MBTL1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE AR, MAPT, NR5A1 RAB9A 1490/4885NPC1 962/4885L3MBTL1 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.